FormDSignal
35

Trellis Bioscience raises $1.35M in indefinite biotech offering under Reg D 506(b)

Company raise · Open-ended · REDWOOD CITY, CA · Form D filed 2026-10-21

Trellis Bioscience, a Delaware biotech corporation based in Redwood City, CA, is conducting an indefinite offering and has sold $1.35M to 9 investors since April 2023. The company is raising under Regulation D exemption 506(b) without general solicitation.

operating_company

Why now — by persona

  • Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock

People on the filing

Nora MendeChief Financial Officer
Larry KauvarChief Science Officer

Signed by Nora Mende, Chief Financial Officer.

Filing contact

The issuer's phone number and address from the filing are shown to subscribers. See plans, or read it on EDGAR.

Other filings by this issuer